Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Pfizer's interest expense for the
three
months ended in Dec. 2023 was $ -688 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-2,209 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Pfizer's Operating Income for the
three
months ended in Dec. 2023 was $ -1,971 Mil. Pfizer's Interest Expense for the
three
months ended in Dec. 2023 was $ -688 Mil.
Pfizer did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Pfizer Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2,209 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pfizer (NYSE:PFE) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Pfizer's Interest Expense for the
three
months ended in Dec. 2023 was $-688 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $-1,971 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $60,499 Mil.
Pfizer's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| Pfizer did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Pfizer (Pfizer) Business Description
Traded in Other Exchanges
Address
66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Executives
| Scott Gottlieb |
director |
MOLECULAR INSIGHT PHARMACEUTICALS, 160 SECOND STREET, CAMBRIDGE MA 02142 |
| Christoffel Boshoff |
officer: Executive Vice President |
66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192 |
| Jennifer B. Damico |
officer: SVP & Controller |
C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
| Payal Sahni |
officer: Executive Vice President |
ATTN: PFIZER CORP. SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017 |
| Carapezzi William R Jr |
officer: Executive Vice President |
600 MOUNTAIN AVENUE, MURRAY HILL NJ 07921 |
| Douglas M Lankler |
officer: Senior Vice President |
PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
| Mikael Dolsten |
officer: Senior Vice President |
5 GIRALDA FARMS, MADISON NJ 07940 |
| David M Denton |
officer: Chief Financial Officer & EVP |
1000 LOWE'S BOULEVARD, MOORESVILLE NC 28117 |
| William Pao |
officer: Executive Vice President |
C/O CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
| Michael Mcdermott |
officer: Executive Vice President |
C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, 235 EAST 42ND STREET NY 10017 |
| Rady A Johnson |
officer: Executive Vice President |
PFIZER INC. ATTN CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
| Alexander R Mackenzie |
officer: Executive Vice President |
C/O PFIZER CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
| Sally Susman |
officer: Senior Vice President |
767 FIFTH AVE, EOTIC LAWDER CORP, NEW YORK NY 10153 |
| Angela Hwang |
officer: Group President |
235 EAST 42ND STREET, ATTN: CORPORATE SECRETARY, NEW YORK NY 10017 |
| John D Young |
officer: Business Unit President |
C/O CORPORATE SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017 |
Pfizer (Pfizer) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PFE has been successfully added to your 